Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to stage-specific embryonic antigen 4 (SSEA-4) are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as breast cancer, lung cancer, esophageal cancer, rectal cancer, biliary cancer, liver cancer, buccal cancer, gastric cancer, colon cancer, nasopharyngeal cancer, kidney cancer, prostate cancer, ovarian cancer, cervical cancer, endometrial cancer, pancreatic cancer, testicular cancer, bladder cancer, head and neck cancer, oral cancer, neuroendocrine cancer, adrenal cancer, thyroid cancer, bone cancer, skin cancer, basal cell carcinoma, squamous cell carcinoma, melanoma, and/or brain tumor.本發明係揭示包含結合至階段特異性胚胎抗原4 （SSEA-4）之抗體或其抗原結合片段之醫藥組合物，以及使用其之方法。使用方法包括但不侷限於，癌症治療及診斷。本發明抗體可結合至特定癌細胞表面。本發明所揭示抗體之示例性標靶可包括癌，如乳癌、肺癌、食道癌、直腸癌、膽道癌、肝癌、頰癌、胃癌、大腸癌、鼻咽癌、腎癌、前列腺癌、卵巢癌、子宮頸癌、子宮內膜癌、胰腺癌、睾丸癌、膀胱癌、頭頸癌、口腔癌、神經內分泌癌、腎上腺癌、甲狀腺癌、骨癌、皮膚癌、基底細胞癌、鱗狀細胞癌、黑色素瘤及/或腦腫瘤。
